SCHEMBL24068638

SCHEMBL24068638

CC(C)(C)OC(=O)N(CCCCCCCC(=O)O)CCCN=[N+]=[N-]

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA14 Q9ULX7 1/20 0.42
HDAC1 Q13547 1/20 0.37
HDAC2 Q92769 1/20 0.37
HDAC6 Q9UBN7 1/20 0.37
FOLH1 Q04609 4/20 0.36
ALDH1A1 P00352 3/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
TSHR P16473 5/20 0.32
LMNA P02545 1/20 0.32
NFKB1 P19838 1/20 0.32
PMP22 Q01453 1/20 0.32
PPARG P37231 6/20 0.31
PPARD Q03181 6/20 0.31
PPARA Q07869 6/20 0.31
GPR84 Q9NQS5 5/20 0.31
HDAC11 Q96DB2 5/20 0.31
TLR2 O60603 2/20 0.31
TDP1 Q9NUW8 2/20 0.31
FABP4 P15090 2/20 0.31
PTPN1 P18031 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23765705 1.00 CA14 (0.42) CA14HDAC1HDAC2HDAC6FOLH1
SCHEMBL23765714 1.00 CA14 (0.42) CA14HDAC1HDAC2HDAC6FOLH1
SCHEMBL23765707 0.99 CA14 (0.43) CA14HDAC1HDAC2HDAC6FOLH1
SCHEMBL25756173 0.95 CA14 (0.42) CA14HDAC1HDAC2HDAC6FOLH1
SCHEMBL25756186 0.95 CA14 (0.42) CA14HDAC1HDAC2HDAC6FOLH1
SCHEMBL23765704 0.95 CA14 (0.41) CA14HDAC1HDAC2HDAC6FOLH1
SCHEMBL24068302 0.92 CA14 (0.44) CA14HDAC1HDAC2HDAC6FOLH1
SCHEMBL23765737 0.89 CA14 (0.41) CA14HDAC1HDAC2HDAC6
SCHEMBL24068389 0.89 CA14 (0.38) CA14HDAC1HDAC2HDAC6FOLH1
SCHEMBL23765706 0.89 CA14 (0.38) CA14HDAC1HDAC2HDAC6FOLH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230210999-A1 TARGETED PROTEASE DEGRADATION (TED) PLATFORM EUBULUS BIOTHERAPEUTICS (HONG KONG) LIMITED (HK) 2023-07-06 US disclosed
US-20230210999-A1 TARGETED PROTEASE DEGRADATION (TED) PLATFORM EUBULUS BIOTHERAPEUTICS (HONG KONG) LIMITED (HK) 2023-07-06 US disclosed
US-20210369853-A1 TARGETED PROTEASE DEGRADATION PLATFORM EUBULUS BIOTHERAPEUTICS INC. (CN) 2021-12-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230210999-A1 TARGETED PROTEASE DEGRADATION (TED) PLATFORM UCHL3, UBE2L3, ADAM33 CA14 2124/4885HDAC1 596/4885HDAC2 1263/4885
US-20210369853-A1 TARGETED PROTEASE DEGRADATION PLATFORM PSMB1, MDM2, XIAP CA14 1481/4885HDAC1 633/4885HDAC2 2081/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.